Regeneron at ASCO 25: Advancing multiple myeloma treatment

Multiple myeloma (MM) is an incurable haematological malignancy, but patient survival outcomes have been lately improved by recent advances in treatment. Despite this innovation, however, MM patients are at high risk of relapse and need prompt treatment to reduce the morbidity and mortality associated with the disease and its complications.

Web editor Nicole Raleigh spoke with Karen Rodriguez-Lorenc, vice president, therapeutic area lead hemato-oncology, at Regeneron to discuss the company’s announcement at ASCO25 of full details of linvoseltamab combination data in relapsed/refractory multiple myeloma.

Rodriguez-Lorenc explains the unmet needs of patients in this area, the potential benefits of the combination data, and discusses the highlights at the Congress this year that indicate future possibilities within oncology.

Watch this and other conversations from ASCO25 here.